IntelGenX Corp.

Saint-Laurent,  QC 
Canada
http://www.intelgenx.com/Home/default.aspx
  • Booth: 1453

IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical films based on its proprietary oral film technology platforms.

Established in 2003, we are based in Montreal, Canada and listed on the TSX-V and OTC-QX.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, intellectual property, regulatory and manufacturing services. 

We offer:

• Contract Development and Manufacturing of Films

• Late Stage Innovative Oral Film Products for Licensing

 

We Make Approved Drugs Better

Brands: VersaFilm™ and VetaFilm™ research and development services and oral film products provide significant market opportunities for improving drug delivery for human and companion animals, respectively.


 Products

  • VersaFilm™ - Versatile Oral Film Technology
    VersaFilm™ versatile film technology enables the development of naturally disintegrating oral products similar in size and thickness to a stamp. VersaFilm™ oral films offer various advantages to meet the needs of patients, caregivers, and physicians....

  • VersaFilm R&D services are based on a versatile drug delivery platform technology that enables the development of oral pharmaceutical films exhibiting improved product performance:

    • Rapid disintegration without the need for water
    • Quicker buccal or sublingual absorption
    • Potential for faster onset of action and increased bioavailability
    • Potential for reduced adverse effects by bypassing first-pass metabolism
    • Easy administration for patients who have problems in swallowing: pediatric, geriatric, fear choking and/or suffering from nausea
    • Pleasant taste
    • Small and thin size, making it convenient for consumers
  • VetaFilm™ - Veterinary Oral Film Technology
    VetaFilm™ is our proprietary veterinary oral film technology that provides significant market opportunities for improving drug delivery for companion animals....

  • VetaFilm™ research and development services and veterinary oral films provide significant market opportunities for improving drug delivery for companion animals:

    • Dose placed directly on oral mucosa or on their favorite treat
    • Designed to adhere on contact
    • Removes the need for syringe handling
    • Increases animal acceptance/ compliance
    • Customized for specific needs
  • Film Development and Manufacturing by Contract
    We offer full service to foster the growth of its partners. Our expert team supports you from pre-development activities up to the commercial manufacturing of oral film products....

  • IntelGenx offers full service to foster the growth of its partners.

    Our State-of-the-art facilities - designed for VersaFilm™ and VetaFilm™ R&D services & film technologies - are equipped with the most modem equipment to deliver high-quality, cost-effective film products, while accommodating client requirements at each stage of product development.

    Our unique experience at all scales of production of pharmaceutical films, including suspensions, solubilizations, monolayer or multilayer film products to name a few, constitutes significant advantages for our customers.

    Our equipment and procedures have been designed to comply with all regulatory standards. Our GMP facility is dedicated to the development and manufacturing of pharmaceutical films. We are licensed to handle narcotics and controlled substances.

    Our team will be pleased to assist you with the batch production for:

    • Tech-transfer
    • Stability
    • Lab-Scale
    • Scale-up
    • Pilot
    • Validation
    • Clinical
    • Commercial

    IntelGenx' expertise and comprehensive development and manufacturing capabilities have the power to transform your ideas into pharmaceutical innovation. 

  • Rizaport® Rizatriptan VersaFilm™ for Migraines
    Rizaport® is a novel, competitive and differentiated oral thin film formulation of rizatriptan for the acute treatment of migraine. Rizaport® is based on IntelGenx oral thin film proprietary drug delivery technology VersaFilmTM....

  • Rizaport® is the first rizatriptan oral disintegrating film for the treatment of migraine to achieve E.U. marketing approval and pending FDA approval.

    Rizaport® Key Licensing Highlights

    • Orally disintegrating film, without need for water, provides exceptional convenience for migraine patients who experience nausea or have trouble swallowing
    • Rizaport® is the first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilmTM, for the acute treatment of migraine with or without aura
    • Containing rizatriptan, one of the most effective triptans
    • Bioequivalent to Maxalt-MLT® (Merck & Co.)
    • The first rizatriptan oral disintegrating film to achieve approval in the E.U. and pending U.S. FDA approval
    • USPTO has granted a patent protecting Rizaport®  for 15+ years
    • Manufactured at IntelGenx through a bona fide process offering better cost-effectiveness compared to Maxalt-MLT®
    • IntelGenx offers strong expertise in formulation and process development as well as manufacturing capability
    • Strong management team with a proven track record of success in working with commercialization partners

    We are currently looking for a partnership or alliance opportunity to commercialize Rizaport® in any territories worldwide apart from Spain and the Republic of Korea.

  • Loxapine VersaFilm™ for agitation in schizophrenia
    Loxapine oral film utilizes IntelGenx' proprietary VersaFilm™ technology to allow for a fast and safe acting loxapine oral film dosage form, offering significant clinical benefits for patients with agitation in schizophrenia & bipolar 1 disorder....

  • Loxapine VersaFilmTM is the first innovative oral thin film of loxapine for use in patients with agitation associated with schizophrenia and bipolar 1 disorder.

    Agitation associated with schizophrenia or bipolar mania can, if left untreated, rapidly escalate into physically aggressive behavior that can be potentially dangerous to the agitated individual and others. In a clinical setting agitation associated with schizophrenia and bipolar mania are often managed with loxapine, a well-known antipsychotic medication.

    IntelGenx has demonstrated in a successful pilot study that buccal absorption of the drug using loxapine VersaFilmTM results in a significantly higher bioavailability compared to oral capsules.

    Loxapine VersaFilmTM Key Licensing Highlights:

    • The first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilmTM, for agitation associated with schizophrenia & bipolar1 disorder
    • Containing loxapine, a well-known molecule in the antipsychotic drug market
    • Fast-acting loxapine oral dosage to treat acute agitation episodes in non-institutionalized patients
    • Oral administration of loxapine is associated with reduced risk of pulmonary complications
    • Orally disintegrating film, without need for water, packaged in a carry-on-the-go pocket size pouch provides unprecedented patient convenience
    • IntelGenx offers strong expertise in formulation and process development as well as manufacturing capability

    IntelGenx plans to establish a strategic partnership for the development and subsequent commercialization of a branded differentiated loxapine film product, loxapine VersaFilmTM

  • Tadalafil VersaFilm™ for Erectile Dysfunction
    Tadalafil VersaFilm™ is the first oral film using IntelGenx proprietary drug delivery technology, VersaFilm™, for erectile dysfunction. Tadalafil VersaFilm™ has successively demonstrated bioequivalence to Cialis®....

  • Tadalafil film is a new product opportunity formulated using VersaFilmTM, IntelGenx’s proprietary thin film technology, which demonstrated successively bioequivalence to Cialis®.

    Tadalafil is considered as the preferred ED drug amongst PDE-5 inhibitors. It allows greater spontaneity for the patient, reducing stress and performance anxiety due to its competitive advantages including a longer duration of action, possibility to be taken without regard to food and effectiveness within approximately 30 minutes after administration. In 2014, the global Cialis® sales were estimated to be US $2.291 billion.


    Tadalafil VersaFilmTM Key Licensing Highlights:

    • The first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilmTM, for erectile dysfunction
    • Containing tadalafil (Cialis® - Eli Lilly), a major molecule in the erectile dysfunction market
    • Demonstrated bioequivalence to Cialis®
    • Orally disintegrating films without need for water provide unprecedented patient convenience and a discrete dosing alternative
    • Exclusive rights from Eli Lilly to commercialize the film in the U.S. translates to opportunity to secure patients ahead of the expected generic tadalafil tablet forms
    • IntelGenx offers strong expertise in formulation and process development as well as manufacturing capability
    • Strong management team with a proven track record of success in working with commercialization partners

    IntelGenx is currently looking for a partnership or alliance opportunity to commercialize tadalafil VersaFilm™.

  • Montelukast VersaFilm™ for Alzheimer’s disease
    Montelukast VersaFilm™ is a unique drug opportunity for the treatment of neurodegenerative diseases of the brain, such as mild cognitive impairment, Alzheimer’s disease and dementia. Ph2a proof of concept study has been initiated....

  • Montelukast VersaFilm™ is an early stage pipeline opportunity that leverages the VersaFilm™ technology for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer's disease, the most prominent form of dementia.


    IntelGenx is working to repurpose montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. Montelukast has been approved by the 
    U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. 

    IntelGenx ' proprietary VersaFilm™ technology is especially suited for special needs patient populations, and Montelukast VersaFilm™product therefore offers many distinct advantages over tablets for Alzheimer’s Disease patients, including the avoidance and minimization of first-pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance.


    IntelGenx has begun preparation for a phase II-a proof-of-concept study. 


    Based on the outcome of this first efficacy trial in humans, IntelGenx will be actively seeking a partnership or alliance opportunity to further advance developmental work and commercialization of Montelukast VersaFilm™.